Brigidbio

Next-Generation immunotherapy for serious fungal infections

Brigid Bio is pioneering the development of novel immunotherapies for the treatment of life-threatening and drug-resistant invasive fungal infections.

As a spinout from the University of Aberdeen, Brigid Bio leverages the world-class scientific expertise of two centres of excellence - Aberdeen Fungal Group and the Scottish Biologics Facility. Our experienced and accomplished team has a strong track record in commercialisation, enabling us to translate cutting-edge science into real-world solutions.

Our mission is to address the urgent demand for safer and more effective antifungal drugs, and ultimately improve clinical outcomes for high-risk patients. By advancing a first-in-class, biologic therapeutics, Brigid Bio is committed to transforming the standard of care for patients most vulnerable to invasive fungal diseases.

IFIs

Invasive fungal infections (IFIs) lead to 3 million deaths globally each year. These infections are on the rise with the ever-increasing numbers of individuals at risk through advances in cancer therapies and other immunosuppressive regimens. Despite receiving best-available treatment, the mortality rate associated with invasive fungal infections remains alarmingly high, at 40-80% and has not improved in the last two decades.

In European ICU’s alone 79 cases of IFIs are diagnosed daily with 37% mortality at 30 days post diagnosis*. Invasive candidiasis and aspergillosis represent the most critical infections for patients in the ICU.*(Koehler et al., 2019)

"The WHO and CDC have categorised fungal infections as a serious threat to public health, highlighting the urgent need for novel therapeutics."

Fungal Priority Pathogen List

WHO-classified pathogens requiring urgent R&D attention

Critical Priority

Candida albicans

Candida auris

Aspergillus fumigatus

Cryptococcus neoformans

High Priority

Nakaseomyces glabrata

Candida tropicalis

Candida parapsilosis

Eumycetoma agents

Histoplasma spp

Mucorales

Fusarium spp

Medium Priority

Scedosporium spp

Lamentospora prolificans

Coccidioides spp

Pichia kudriavzeveii

Cryptococcus gattii

Talaromyces marneffei

Pneumocystis jirovecii

Paracoccidioides spp

Candida auris — Urgent Global Superbug Threat

The CDC has declared Candida auris an urgent “superbug” due to its high mortality rate, multidrug resistance, and rapid spread in healthcare facilities.

Clinical Gap

Limitations of Current Antifungal Therapies

Complex drug-drug interactions (DDIs)

When used in combination with chemotherapy and other immunosuppressive regimens, antifungals cause deleterious drug-drug interactions.

Inherent Drug Toxicity

Due to the shared cellular structures and metabolic pathways in fungi and humans, certain antifungals have a high risk of liver and kidney toxicity in patients.

Antifungal Drug Resistance (AFR)

Emergence of multidrug resistant pathogens like Candida auris, Candida glabrata and Aspergillus fumigatus are resulting in treatment failures.

Lengthy hospital stays

Current dosing frequency results in 1 in 7 candidemia patients being kept in hospitals for antifungal administration alone, leading to longer hospital stays and increased treatment costs.

What Sets Us Apart

Explore the key features that make our next-generation immunotherapy a game-changer in this critical area of unmet medical need.

First in class human mAbs

Novel mechanism of action that selectively boosts immune system

Pan fungal activity

Covers key fungal pathogens and drug-resistant Candida, Aspergillus and Rhizopus spp

No DDIs

Proven safety profile enables continuation of cancer therapy

Reduced hospital stay

Increased biological half-life enabling once a month vs daily/weekly dosing

A Novel Approach To Treat Invasive Fungal Infection (IFI)

Science

Our patented drug discovery platform integrates proteomics and transcriptomics to identify key fungal cell wall markers critical for survival during infection and resistance. Using advanced antibody technologies and guided epitope selection, we have developed fully human monoclonal antibodies targeting the surface exposed regions of unique fungal cell wall proteins.

Our novel drug targets are fungal specific cell wall remodelling proteins with no human homologues.

Cell wall proteins are overexpressed upon antifungal challenge and in drug-resistant clinical isolates of key fungal pathogens, enhancing mAb binding when administered with standard of care.

The mAbs have proven efficacy in ‘clinically predictive’ mouse models of disseminated candidiasis, both in immunocompetent and immunocompromised mice models

Brigid Bio mAbs bind surface-exposed peptide epitopes identified by our proprietary drug discovery platform

Novel Panfungal Drug Targets

Fully human therapeutic antibodies targeting unique cell wall proteins conserved in yeasts and moulds

(Candida & Aspergillus spp)

Superior Potency Fully Human mAbs

Brigid Bio mAbs are high-potency neutralising antibodies — far exceeding low-potency competitor sugar binders

Synergistic Co-Therapy

Demonstrates enhanced binding when combined with standard of care antifungals – Echinocandins & Azoles

Increased Binding in Resistance

mAb binding increases in drug resistant strains - a unique advantage

Disruption of Immune Evasion

Cell wall targets are overexpressed during macrophage engulfment boosting immune response

Our Team

Team

Chris Jones

Executive Chairman

Dr Soumya Palliyil

CEO & Co-Founder

Prof Carol Munro

CSO & Co-Founder

Prof Andy Porter FRSE

CTO & Co-Founder

David Armour

CFO

Dr Daniel Smith

Senior Scientist

Dr Yixin Zhao

Senior Scientist

Advisors

Dr Dan Ozanne

CMC Advisor

Prof Mahamoud Ghannoum

Advisor Preclinical Dev

Dr Kirsty Wydenbach

Advisor Regulatory

Dr Nicola Walls

Advisor Clinical Trials

Prof Frank van de Veerdonk

Clinical Advisor

Latest Updates

May 07, 2026

Brigid Bio's monoclonal antibody based immunotherapy approach has been featured in The Lancet's coverage of the Fungal Update: Mycology Conference 2026

At Mycology Conference 2026, Prof Carol Munro presented promising preclinical data on our pan-fungal, first in class human monoclonal antibodies and their proven efficacy in invasive fungal infections in immunosuppressed and immunocompetent models. These antibodies are designed to target novel fungal cell wall proteins, present in Candida and Aspergillus spp representing a significant breakthrough in the fight against invasive fungal infections.

April 23, 2026

Brigid Bio Co-Founders Honoured at University of Aberdeen Principal’s Excellence Awards

The co-founders of Brigid Bio Ltd - Professor Carol Munro, Dr Soumya Palliyil, and Professor Andy Porter - have been recognised at the prestigious University of Aberdeen Principal’s Excellence Awards for their outstanding contributions to scientific research and entrepreneurship.

February 24, 2026

Brigid Bio to attend 10th AMR Conference in Basel 3-4th March 2026!

Brigid Bio is excited to announce attendance at the 10th Antimicrobial Resistance (AMR) Conference in Basel 3-4th March 2026, a leading event for innovators in anti-infectives.

Read All Updates

Get In Touch

If you would like further information about our solution, please get in contact with us.

We would love to hear from Oncologists, Infectious Disease Consultants, and R&D specialists within the Biotech and Pharma industries.

Connect on LinkedIn

Brigid Bio, Liberty Building
Foresterhill Health Campus
Foresterhill Rd, Aberdeen AB25 2ZP